Sitagliptin, a novel treatment for type II diabetes

Original broadcast date: January 13, 2008

The prevalence of type  II diabetes continues to increase and estimates are that three million Canadians will be diagnosed with the disease by 2010. The mainstays of control and prevention, weight loss and exercise, are not always heeded, and as such, medications are employed to control blood sugar levels.

A new medication called sitaglipin (Januvia) has been approved this month by Health Canada. It employs a different mechanism of action compared to the medications that are in use today.

  • Dr. Daniel J. Drucker, Endocrinologist and Professor of Medicine in the Division of Endocrinology, Department of Medicine, University of Toronto.
    Director, Banting and Best Diabetes Centre, University of Toronto, Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Send a Comment

Your email address will not be published.

Bitnami